Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The "SMART" side of hypertriglyceridemia.

Atherosclerosis·2025
Same author

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis.

Clinical rheumatology·2025
Same author

Clínica e Investigación en Arteriosclerosis, the Iberoamerican journal of lipidology and vascular risk.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2022
Same author

Serum sex hormone-binding globulin levels are reduced and inversely associated with intrahepatic lipid content and saturated fatty acid fraction in adult patients with glycogen storage disease type 1a.

Journal of endocrinological investigation·2022
Same author

High protein prescription in methylmalonic and propionic acidemia patients and its negative association with long-term outcome.

Clinical nutrition (Edinburgh, Scotland)·2021
Same author

Preferences of people with Type 2 diabetes for diabetes care: a discrete choice experiment.

Diabetic medicine : a journal of the British Diabetic Association·2019
Same journal

Overview of Novel Mechanisms in Obesity Pharmacotherapy and Implications for Cardiovascular Disease: A Narrative Review.

Current atherosclerosis reports·2026
Same journal

Artificial and Other Non-Nutritive Sweeteners, the Microbiome, and Cardiometabolic Health.

Current atherosclerosis reports·2026
Same journal

Single-cell Technologies in Atherosclerosis: Uncovering Cellular Heterogeneity, Mechanisms, and Therapeutic Opportunities.

Current atherosclerosis reports·2026
Same journal

Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.

Current atherosclerosis reports·2026
Same journal

Comparative Efficacy of Nutraceuticals on Endothelial Function: A Systematic Review and Network Meta-Analysis.

Current atherosclerosis reports·2026
Same journal

Familial Hypercholesterolemia in Women: Diagnosis, Treatment, and Cardiovascular Outcomes Across the Lifespan.

Current atherosclerosis reports·2026
See all related articles

Related Experiment Video

Updated: May 17, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.1K

Familial Combined Hyperlipidemia: Myth or Reality?

M C G J Brouwers1,2, B Klop3, J Ribalta4,5,6

  • 1Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht UMC+, Maastricht, the Netherlands.

Current Atherosclerosis Reports
|April 1, 2025
PubMed
Summary
This summary is machine-generated.

Familial combined hyperlipidemia (FCHL) is a polygenic disorder, not solely defined by specific gene variants. Current understanding shifts focus from a single gene to multiple genetic factors influencing lipid levels.

Keywords:
Fatty liver diseaseFree fatty acidsHyperlipidemiaTriglyceridesVLDL overproduction

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.9K
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.0K

Related Experiment Videos

Last Updated: May 17, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.1K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.9K
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.0K

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Cardiovascular Disease

Background:

  • Familial combined hyperlipidemia (FCHL) was initially described in 1973 as an autosomal dominant disorder associated with premature myocardial infarction.
  • The definition and genetic basis of FCHL have been subjects of ongoing research and debate.

Purpose of the Study:

  • To provide a historical overview of the metabolic and genetic abnormalities characterizing FCHL.
  • To integrate historical findings with recent genetic and population studies to propose a new pathophysiological concept of FCHL.
  • To offer practical guidance for managing patients with an FCHL phenotype.

Main Methods:

  • Review of historical literature on FCHL.
  • Analysis of quantitative trait linkage studies.
  • Inclusion of data from genome-wide association studies (GWAS) and next-generation sequencing (NGS).
  • Integration of findings from recent population-based and genetic studies.

Main Results:

  • FCHL is confirmed as a polygenic disorder, with multiple associated gene variants, primarily affecting triglyceride levels.
  • The identified gene variants are not unique to FCHL.
  • The multiple-type hyperlipidemia phenotype is not exclusively confined to FCHL.
  • A new pathophysiological model for FCHL has been developed based on integrated findings.

Conclusions:

  • FCHL is a complex polygenic condition, challenging the initial autosomal dominant model.
  • The understanding of FCHL requires integration of historical metabolic data with modern genetic insights.
  • The proposed model offers a framework for clinical management of individuals presenting with FCHL phenotypes.